Chinook Therapeutics to Present at Upcoming Investor Conferences
April 11, 2023 16:00 ET
|
Chinook Therapeutics, Inc.
SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Announces Voluntary Pause in Dosing of CHK-336 in Ongoing Phase 1 Clinical Trial in Healthy Volunteers
April 11, 2023 08:00 ET
|
Chinook Therapeutics, Inc.
SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 07, 2023 16:00 ET
|
Chinook Therapeutics, Inc.
SEATTLE, April 07, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics to Present at the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days
March 28, 2023 16:00 ET
|
Chinook Therapeutics, Inc.
SEATTLE, March 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Announces Upcoming Presentations at ISN World Congress of Nephrology 2023
March 23, 2023 08:00 ET
|
Chinook Therapeutics, Inc.
SEATTLE, March 23, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
March 07, 2023 16:00 ET
|
Chinook Therapeutics, Inc.
SEATTLE, March 07, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 03, 2023 16:00 ET
|
Chinook Therapeutics, Inc.
SEATTLE, March 03, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Announces Upcoming Presentations at the 5th Chronic Kidney Disease Drug Development Summit
February 28, 2023 08:00 ET
|
Chinook Therapeutics, Inc.
SEATTLE, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
February 27, 2023 16:00 ET
|
Chinook Therapeutics, Inc.
SEATTLE, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Announces the Appointment of Andrew Oxtoby as Chief Commercial Officer
February 15, 2023 08:00 ET
|
Chinook Therapeutics, Inc.
SEATTLE, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...